MLchartDataset catalogue

DHX9 inhibitor ATX-559

Term · Oncology and biomedicine · MLC-T-ONC-013029

An orally bioavailable inhibitor of the protein RNA helicase A (DHX9; DDX9; RHA), with potential antineoplastic activity. Upon oral administration, DHX9 inhibitor ATX-559 targets, binds to and inhibits DHX9. This may cause genomic instability and may lead to DNA replication stress and DNA damage, and may induce apoptosis in certain vulnerable cancer cells. DHX9, a multi-functional RNA helicase, is involved in the maintenance of genomic stability by resolving DNA/RNA secondary structures that may lead to DNA replication stress and DNA damage in certain molecularly defined cancers.

Table 1. Record
IdentifierMLC-T-ONC-013029
FieldOncology and biomedicine
Synonymshelicase DHX9 inhibitor ATX-559; RNA helicase A inhibitor ATX-559
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013029",
  "term": "DHX9 inhibitor ATX-559",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the protein RNA helicase A (DHX9; DDX9; RHA), with potential antineoplastic activity. Upon oral administration, DHX9 inhibitor ATX-559 targets, binds to and inhibits DHX9. This may cause genomic instability and may lead to DNA replication stress and DNA damage, and may induce apoptosis in certain vulnerable cancer cells. DHX9, a multi-functional RNA helicase, is involved in the maintenance of genomic stability by resolving DNA/RNA secondary structures that may lead to DNA replication stress and DNA damage in certain molecularly defined cancers.",
  "synonyms": [
    "helicase DHX9 inhibitor ATX-559",
    "RNA helicase A inhibitor ATX-559"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dhx9-inhibitor-atx-559/"
}

Record 5,926 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.